Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Vertex Pharmaceuticals (VRTX) stock in plain English

Free brief · no signupStart here
VRTXPublished Nov 12, 2026
Vertex Pharmaceuticals Inc
Healthcare · Biotechnology
Manufactures and sells prescription medicines that correct defective proteins causing cystic fibrosis. Develops gene therapies and targeted treatments for rare blood and kidney disorders.
Assets:
Trikafta franchiseTreats up to ninety percent of cystic fibrosis patients worldwide
Boston headquartersHouses research laboratories and operations in the Seaport District
Casgevy therapyCommercial CRISPR gene-editing treatment for severe blood disorders
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

72
OPS ScoreOperating finances
Latest quote
-2.94%$520.66
$132.01B
33.5×
$13.02B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 12, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was VRTX. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Vertex Pharmaceuticals (VRTX) do?

Vertex Pharmaceuticals Inc (VRTX) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Manufactures and sells prescription medicines that correct defective proteins causing cystic fibrosis. Develops gene therapies and targeted treatments for rare blood and kidney disorders. It controls the global market for medicines treating the underlying genetic cause of cystic fibrosis. It is worth $132.01B on the market and sold $13.02B over the last year.

Market cap
$132.01B
P/E ratio
33.5×
Annual sales
$13.02B
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 12, 2026

Brands and businesses behind VRTX

  • Trikafta: Triple-combination cystic fibrosis therapy sold to pharmacies and healthcare providers worldwide.
  • Casgevy: Gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia sold through specialized hospitals.
  • Kalydeco: Oral cystic fibrosis medicine prescribed to patients with specific responsive genetic mutations.
  • Symdeko: Combination medicine for cystic fibrosis patients carrying two copies of the F508del mutation.
  • Orkambi: Prescription medicine targeting cystic fibrosis in pediatric and adult patients.

VRTX’s flags, in plain English

Each flag is a number from Vertex Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 12, 2026.

Fat Margins

Profit margin of 30.5%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.

Wide Gross Margin

Gross margin of 85.6% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Stupid Cash

Can pay this year's bills 2.3 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Priced for Perfection

Priced at 33.5 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about VRTX

How big is Vertex Pharmaceuticals?

Vertex Pharmaceuticals’ market cap is $132.01B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $13.02B: what customers paid the company over the last year, before any costs.

What is VRTX’s P/E ratio?

VRTX’s P/E ratio is 33.5×. Investors pay about 33.5 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with VRTX?

Cystic fibrosis treatments generate almost all of the company's current sales. That is one risk on Vertex Pharmaceuticals’ card. Its first risk flag is Priced for Perfection, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Vertex Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. VRTX’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card